<DOC>
	<DOC>NCT01624142</DOC>
	<brief_summary>A study to assess the long term safety and efficacy of Evolocumab (AMG145)on Low Density Lipoprotein-Cholesterol (LDL-C) in subjects with severe familial hypercholesterolemia.</brief_summary>
	<brief_title>Trial Assessing Long Term USe of PCSK9 Inhibition in Subjects With Genetic LDL Disorders</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type II</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Participated in a qualifying Evolocumab (AMG145) parent protocol OR Have a diagnosis of familial hypercholesterolemia AND Males and females ≥ 12 to ≤ 80 years of age Stable lowfat diet and lipidlowering therapies for at least 4 weeks Low Density Lipoprotein Cholesterol (LDLC) &gt;=130 mg/dl (3.4 mmol/L) for subjects without diagnosed CHD/CHD risk equivalent OR LDLC &gt;= 100 mg/dl (2.6 mmol/L) for subjects with diagnosed CHD or CHD risk equivalent OR apheresis patients have no LDLC entry requirement Fasting triglycerides &lt; 400 mg/dL(4.5 mmol/L) Bodyweight of &gt; 40 kg or greater at screening for subjects less than 18 years of age New York Heart Failure Association (NYHA) class III or IV or last known left ventricular ejection fraction &lt; 30% Myocardial infarction, unstable angina, percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG) or stroke within 3 months of screening Planned cardiac surgery or revascularization Uncontrolled cardiac arrhythmia Uncontrolled hypertension</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Hypercholesterolemia</keyword>
	<keyword>Elevated Cholesterol</keyword>
	<keyword>High Cholesterol</keyword>
	<keyword>Homozygous Familial Hypercholesterolemia</keyword>
	<keyword>PCSK9 mutations</keyword>
	<keyword>Severe Familial Hypercholesterolemia</keyword>
</DOC>